Drug Trial Radar · NCT03536884
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
743
Actual
Start
Jun 13, 2018
Primary completion
Sep 12, 2019
Study completion Aug 9, 2023
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- May 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
Conditions
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
Interventions
BimekizumabDrug
Subjects will receive bimekizumab at pre-specified time-points.
SecukinumabDrug
Subjects will receive secukinumab at pre-specified time-points.
PlaceboOther
Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16Time frame: Week 16
Locations
77 sites in 11 countries. Site status is shown where the registry gives one.
Ps0015 975
Santa Ana, California
Ps0015 939
Danbury, Connecticut
Ps0015 903
Ocala, Florida
Ps0015 921
Ormond Beach, Florida
Ps0015 977
Pembroke Pines, Florida
Ps0015 936
Tampa, Florida
Ps0015 976
Tampa, Florida
Ps0015 970
West Palm Beach, Florida
Ps0015 966
Sandy Springs, Georgia
Ps0015 954
Skokie, Illinois
Ps0015 972
West Dundee, Illinois
Ps0015 900
West Des Moines, Iowa
Ps0015 944
New Orleans, Louisiana
Ps0015 915
Clayton, Missouri
Ps0015 953
St Louis, Missouri
Ps0015 901
Portsmouth, New Hampshire
Ps0015 965
Kew Gardens, New York
Ps0015 969
High Point, North Carolina
Ps0015 971
Wilmington, North Carolina
Ps0015 980
Bexley, Ohio
Ps0015 920
Portland, Oregon
Ps0015 929
Portland, Oregon
Ps0015 979
Dallas, Texas
Ps0015 924
Houston, Texas
Ps0015 978
Pflugerville, Texas
PS0015 3
Carlton, Australia
PS0015 7
Hectorville, Australia
PS0015 6
Kogarah, Australia
Ps0015 11
Parkville, Australia
PS0015 9
Woolloongabba, Australia
Ps0015 50
Brussels, Belgium
Ps0015 54
Brussels, Belgium
Ps0015 52
Liège, Belgium
Ps0015 673
Halifax, Canada
Ps0015 671
Hamilton, Canada
Ps0015 663
Mississauga, Canada
Ps0015 661
Peterborough, Canada
Ps0015 678
Richmond Hill, Canada
Ps0015 677
Toronto, Canada
Ps0015 657
Waterloo, Canada
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.